Cytek Biosciences Inc - Asset Resilience Ratio

Latest as of March 2026: 43.77%

Cytek Biosciences Inc (CTKB) has an Asset Resilience Ratio of 43.77% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cytek Biosciences Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$196.56 Million
Cash + Short-term Investments

Total Assets

$449.11 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Cytek Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Cytek Biosciences Inc balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Cytek Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Cytek Biosciences Inc debt and liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $196.56 Million 43.77%
Total Liquid Assets $196.56 Million 43.77%

Asset Resilience Insights

  • Very High Liquidity: Cytek Biosciences Inc maintains exceptional liquid asset reserves at 43.77% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Cytek Biosciences Inc Industry Peers by Asset Resilience Ratio

Compare Cytek Biosciences Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Medtronic plc
SA:MDTC34
Medical Devices 7.82%
Demant A/S
CO:DEMANT
Medical Devices -2.59%
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.84%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 34.37%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%
Theradiag SA
PA:ALTHE
Medical Devices 15.59%
Biosynex
PA:ALBIO
Medical Devices 3.35%

Annual Asset Resilience Ratio for Cytek Biosciences Inc (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Cytek Biosciences Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 36.98% $170.68 Million $461.54 Million +1.11pp
2024-12-31 35.86% $179.15 Million $499.50 Million +16.63pp
2023-12-31 19.24% $95.11 Million $494.46 Million +10.66pp
2022-12-31 8.58% $44.55 Million $519.48 Million --
2021-12-31 0.00% $0.00 $463.31 Million --
pp = percentage points

About Cytek Biosciences Inc

NASDAQ:CTKB USA Medical Devices
Market Cap
$672.83 Million
Market Cap Rank
#11474 Global
#2960 in USA
Share Price
$5.21
Change (1 day)
+5.68%
52-Week Range
$3.36 - $5.88
All Time High
$27.93
About

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more